Jupiter Asset Management Ltd. Increases Holdings in Gilead Sciences, Inc. $GILD

Jupiter Asset Management Ltd. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,910 shares of the biopharmaceutical company’s stock after purchasing an additional 5,790 shares during the period. Jupiter Asset Management Ltd.’s holdings in Gilead Sciences were worth $1,830,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. Legal & General Group Plc raised its stake in Gilead Sciences by 1.0% in the fourth quarter. Legal & General Group Plc now owns 10,317,613 shares of the biopharmaceutical company’s stock worth $1,266,384,000 after buying an additional 107,014 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Gilead Sciences by 5.9% in the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after buying an additional 400,002 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after buying an additional 726,101 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 53,000 shares of company stock worth $7,075,670. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $134.43 on Friday. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The stock has a fifty day moving average price of $135.30 and a 200-day moving average price of $134.09. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a market cap of $166.90 billion, a PE ratio of 18.31 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Barclays assumed coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective for the company. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Truist Financial reissued a “buy” rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Sanford C. Bernstein reissued an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Scotiabank boosted their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.